Search results
Results from the WOW.Com Content Network
United States of America v. Regenerative Sciences, LLC, 741 F.3d 1314 (D.C. Cir. 2014), [1] was a decision in the United States Court of Appeals for the District of Columbia Circuit filed on February 4, 2014 concerning more than minimally manipulated cell therapies and whether they are considered part of medical practice or a drug, the latter subjecting it to regulation under the Food and Drug ...
An FDA decision not to grant fast track status, or any other general dispute, may be appealed to the division responsible for reviewing the application within the Center for Drug Evaluation and Research. The drug sponsor can subsequently utilize the Agency's procedures for internal review or dispute resolution if necessary.
The FDA began enforcing its new powers against drug manufacturers who could not substantiate the efficacy claims made for their drugs, and the United States Court of Appeals for the Ninth Circuit ruling in Alberty Food Products Co. v. United States (1950) found that drug manufacturers could not evade the "false therapeutic claims" provision of ...
The Food and Drug Administration has finalized its decision to call an end to the drug shortage of Eli Lilly's blockbuster GLP-1 products, often referred to by their formula name, tirzepatide. Eli ...
Not all FDA decisions have to be painful. On Friday, Johnson & Johnson (NYS: JNJ) got its extended-release version of Nucynta approved by the FDA. The immediate-release version of the pain ...
The bottom line is that the decision upholds the Food and Drug Administration’s rules for mifepristone. ... The Food and Drug Administration approved mifepristone as part of a two-drug protocol ...
Food and Drug Administration v. Alliance for Hippocratic Medicine , 602 U.S. 367 (2024), was a United States Supreme Court case to challenge the U.S. Food and Drug Administration (FDA)'s approval of mifepristone , a drug frequently used in medical abortion procedures.
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...